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Abstract
Pharmacovigilance, defined as "the science and activities relating to the detection, assessment,
understanding and prevention of adverse effects or any other possible drug related problem", is
increasingly being recognized in Africa. Many African countries have simultaneously adopted
artemisinin derivative based combination therapy (ACT) as first-line treatment for uncomplicated
malaria, offering an opportunity to assess the safety of these drugs when used widely. While ACTs
appear to be safe and well-tolerated, there is little experience with these medicines in Africa,
outside clinical trials.
Pharmacovigilance for ACTs and other combination treatments in Africa is essential. Malaria
transmission intensity is high and antimalarial medicines are used frequently. Presumptive treatment
of fever with antimalarials is common, often in the absence of a confirmed diagnosis, using drugs
obtained without a prescription. Informal use of antimalarial drugs may increase the risk of
incorrect dosing, inappropriate treatment, and drug interactions, which may impact negatively on
drug safety. Furthermore, the administration of antimalarial treatments in patients with a
concomitant illness, including HIV/AIDs, tuberculosis and malnutrition, is a concern.
African countries are being encouraged to establish pharmacovigilance systems as ACTs are rolled
out. However, pharmacovigilance is difficult, even in countries with a well-developed health care
system. The rationale for pharmacovigilance of antimalarial drugs is discussed here, outlining the
practical challenges and proposing approaches that could be adopted in Africa.
Background
Prior to product registration and marketing, data about
the safety and efficacy of drugs are limited to observations
from pre-clinical animal studies and initial clinical trials
(Phase I-III). This is the basis for the summary of product
characteristics or the label of the product. Although such
trials are useful for product registration, they typically
evaluate only a small number of specifically selected par-
ticipants under ideal conditions and have limited statisti-
cal power to detect the uncommon side effects. As a result,
clinical trials and the information that is derived from
them are inadequate for the full assessment of safety risks.
Consequently, pharmacovigilance (PV), conducted con-
tinuously from the time a drug is developed to the post-
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marketing phase, becomes critical in evaluating safety
risks. Pharmacovigilance has been defined as "the science
and activities relating to the detection, assessment, under-
standing and prevention of adverse effects or any other
possible drug-related problem" [1]. The term "post-mar-
keting surveillance" (PMS) is sometimes interchangeably
used with PV. However, PV and PMS differ in the features
evaluated and in the timing of the surveillance (Figure 1).
PV primarily focuses on the assessment of safety risks and
begins in the pre-market phase, continuing after the prod-
uct is released onto the market. PMS involves monitoring
the quality, efficacy and safety of registered products that
are already available on the market.
Rationale for pharmacovigilance of antimalarial drugs
Interest in establishing systems for pharmacovigilance of
antimalarial drugs in Africa is gaining momentum [2]. In
response to widespread resistance to older antimalarial
drugs, many African countries have adopted combination
therapy (generally ACT) as first-line therapy for treatment
of uncomplicated malaria, and are planning to use these
new regimens on a wide scale in the public and private
sector. ACTs have been used successfully in Southeast Asia
and appear to be safe and well-tolerated [3-5]. However,
there is relatively little experience with these drugs in
Africa, where malaria transmission intensity is substan-
tially greater and the pattern of antimalarial drug use is
quite different. In areas of intense transmission, antima-
larial drugs are given repeatedly to treat frequent fevers
(even in the absence of malaria). In addition, the use of
antimalarial drugs outside the formal health sector, often
for presumptive treatment of fever, is a widespread prac-
tice in Africa [6-9]. In Uganda, for example, a study con-
ducted at seven sites around the country found
chloroquine metabolites in the urine of 32–80% of the
general population [10]. Antimalarials are often pur-
chased from drug shops or pharmacies without consulting
a health care worker. Such informal use of antimalarials
could increase the risk of incorrect dosing, inappropriate
treatment and interactions of different medicines, which
could have a negative impact on antimalarial treatment
safety. In addition, the safety of antimalarial treatment in
vulnerable populations including pregnant women, and
in patients with coexisting illnesses (such as HIV/AIDs,
tuberculosis and malnutrition) has not yet been estab-
lished. The current plans for wide-scale implementation
of ACTs across Africa offer an important opportunity to
evaluate the safety of medicines. Identification of rare and
unexpected adverse events and evaluation of antimalarial
treatment safety in early pregnancy are high priorities for
PV of ACTs. However, PV is challenging, even in countries
with well-developed health care systems. To develop prac-
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tical and sustainable PV systems in Africa, innovative solu-
tions will be required.
Practical challenges for establishing pharmacovigilance 
systems in Africa
The critical definitions in pharmacovigilance are summa-
rized in Table 1[11]. It is important to recognize the dis-
tinction between an "adverse event (AE)" and an "adverse
drug reaction" (ADR). While an adverse event is any unde-
sirable medical occurrence that develops after the admin-
istration of a drug, regardless of the suspected relationship
between the drug product and the event, to classify an
event as an adverse drug reaction, a causal relationship
must be established. These definitions highlight some of
the practical challenges of establishing a PV system for
antimalarial treatment in Africa, related to the detection
of adverse events and the determination of the severity
and relationship of events to a specific product. Health
workers at the point of data collection are required to
detect adverse events, which are often difficult to distin-
guish from common symptoms of malaria. Once an
adverse event has been detected, the maximum severity of
the event should be established. Standardized guidelines
have been provided by the World Health Organisation
(Table 2) and other organizations [11], but the grading
may be subjective. Classification of the relationship of an
adverse event to a product is another challenge (Table 3).
Determining if an event has been caused by a given prod-
uct or is related to other concomitantly administered
drugs, malaria, or other illnesses, is also difficult and often
subjective. In addition, defining the period of "reasonable
temporal association" between an event and prior treat-
ment is problematic when considering combination ther-
apies that include partner drugs with long elimination
half-lives. Assigning a causal relationship and determin-
ing if an event is unexpected is even more difficult when
multiple drugs have been administered together.
Other challenges related to the reporting procedures
include: What events should be reported? All adverse
events or only adverse drug reactions? Should all events be
reported irrespective of severity grade? Or should only
more severe events be reported? Should the relationship
and expectedness of events impact on reporting? African
national malaria control programmes (NMCPs) and
national drug regulatory authorities will have to address
such questions before PV for antimalarial treatments can
be established.
Application of pharmacovigilance (PV) methods in Africa
Two broad approaches for pharmacovigilance are used in
developed countries, including passive spontaneous
reporting systems, and systems utilising pharmaco-epide-
miological methods. Both methods could be applied in
Africa depending on the circumstances. Potential
approaches of utilizing these methods in Africa are sug-
gested here.
Table 1: Important definitions for PV (ICH guidelines [11])
ADVERSE EVENT
Any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product and which does not 
necessarily have a causal relationship with this treatment. An AE can therefore be any unfavourable and unintended sign (that could include a 
clinically significant abnormal laboratory finding), symptom or disease temporally associated with the use of a medicinal product, whether or not 
considered related to the medicinal product (ICH guidelines).
ADVERSE DRUG REACTION
Any noxious and unintended responses to a medicinal product related to any dose. The phrase "responses to a medicinal product" implies that a 
causal relationship between a medicinal product and an adverse event (AE) is at least a reasonable possibility (i.e. the relationship can not be ruled 
out).
UNEXPECTED ADVERSE DRUG REACTION
An adverse reaction, the nature or severity of which is not consistent with the applicable product information (e.g. investigators brochure for an 
unapproved product or package insert/summary of product characteristics for an approved product (ICH guidelines).
SERIOUS ADVERSE EVENT
Any untoward medical occurrence that at any dose: results in death; is life-threatening; requires hospitalization (other than for drug administration) 
or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect and also 
other important medical events that jeopardise the subject or require intervention to prevent one of the other outcomes listed in the definition 
above).Malaria Journal 2006, 5:50 http://www.malariajournal.com/content/5/1/50
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Passive follow-up of marketed products post-authorisation
Generally, post-authorisation follow-up is done using a
passive approach with continuous reporting of adverse
events and re-evaluation of the risks and benefits of drugs.
Advantages of a passive reporting system include low cost,
simplicity and the ability to detect rare events and contin-
uously monitor safety. However, passive reporting sys-
tems are currently limited or non-existent in most
countries in sub-Saharan Africa, but they could be
strengthened (or developed) by focusing on designated
sentinel health facilities such as district hospitals, and tar-
geted populations such as pregnant women and children
less than five years of age. Potential challenges should be
recognized at the outset including the risk of under-
reporting, and the difficulty of establishing a causal rela-
tionship between adverse events and specific drugs. A rou-
tine PV system for antimalarial treatments in Africa could
be initially targeted to capture data on severe events, and
those deemed to be related to antimalarial drugs. Estab-
lishing a system for passive post-authorisation follow-up
as a basis for signal detection should be a long term com-
mitment of national governments in Africa. The national
drug regulatory agencies should work closely with the
national malaria control programmes and other relevant
programmes such as AIDS control programmes to provide
stewardship. Multi-disciplinary national PV centres
should be established and their capacity should be
strengthened for regular analysis of safety data to identify
and review signals, generate hypotheses, and to ensure
regular reporting and feedback.
Pharmacoepidemiological methods
Post-licensure clinical trials to assess effectiveness and safety of 
medicines in the "real world"
Phase IV studies, unlike Phase III clinical trials aim to eval-
uate the performance of drugs in a "real world" setting,
with minimal interference. A number of post-licensure
antimalarial drug efficacy trials conducted in Africa have
assessed safety, suggesting that Phase IV studies are a fea-
sible approach for PV in an African setting [12-17]. How-
ever, in order to adequately assess safety risk in such
studies, the sample size estimation should ideally be
based on a primary safety outcome, rather than efficacy or
effectiveness, which may necessitate evaluation of a large
number of patients in multiple settings. The main practi-
cal challenges for monitoring safety in such studies are
likely to be similar to those encountered in Phase III clin-
ical trials – specifically, how to differentiate events related
to antimalarial treatments from symptoms of malaria or
other illnesses, and how to establish the severity, relation-
ship and expectedness of adverse events. In Phase III clin-
ical trials, comparison of multiple treatment groups is
used to test hypotheses that efficacy and safety varies with
antimalarial treatment. This approach could also be
applied to Phase IV studies, if the sample size is adequate
to assess risks in multiple arm treatments, and if the col-
Table 3: Relationship of adverse events to antimalarial agents
Classification Definition
Definitely related Events have no uncertainty in their relationship to test drug administration: meaning that a re-challenge was positive.
Probable The suspected adverse event follows a reasonable temporal sequence from study drug administration, abates upon 
discontinuation of the drug, and cannot be reasonably explained by the known characteristics of the subject's clinical 
state.
Possible The suspected adverse event may or may not follow a reasonable temporal sequence from study drug administration 
but seems to be the type of reaction that cannot be dismissed as unlikely. The event could have been produced or 
mimicked by the subject's clinical state or by other modes of therapy concomitantly administered to the subject.
Unlikely There is no reasonable temporal association between the study drug and the suspected event and the event could have 
been produced by the subject's clinical state or other modes of therapy administered to the subject.
Definitely unrelated Events which occur prior to test drug administration or for those events which cannot be even remotely related to 
study participation (e.g. injury caused by a third party).
Table 2: Guidelines for grading severity of adverse events
Grade Severity Description
1 Mild Awareness of sign or symptom, but easily tolerated: Transient or mild discomfort; no limitation in 
activity; no medical intervention/therapy required
2 Moderate Discomfort enough to cause interference with usual activity: some assistance may be needed; no or 
minimal medical intervention required
3 Severe Incapacitating with inability to work or perform usual activity: some assistance usually required; 
hospitalization possible
4 Life-threatening Extreme limitation in activity, significant assistance required; significant medical intervention/therapy 
required; hospitalization probableMalaria Journal 2006, 5:50 http://www.malariajournal.com/content/5/1/50
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lection of safety data is standardized to ensure high qual-
ity. In the past, the need for pharmacovigilance was less
recognized and antimalarial drugs were simply released
on the market, with little PV and PMS. The suggestion that
newer antimalarial drugs be monitored closely after regis-
tration is not meant to imply that these drugs are more
harmful than older drugs. Post-licensure clinical trials are
important and should be supported by the pharmaceuti-
cal industry, working in close collaboration with research-
ers and academia. Indeed in developed countries, PV is a
legal obligation for the pharmaceutical industry. Pharma-
ceutical companies should also support African countries
to conduct post-licensure surveillance, focusing on safety
risks for newer products, as part of their social responsibil-
ity.
Case control studies
Case-control studies could be used to retrospectively eval-
uate newly detected ADRs and assess the risk of adverse
events among patients exposed to a given drug. Such stud-
ies are useful for evaluating rare events and can frequently
be conducted quickly, using a small sample size, at rela-
tively low cost. Case control studies are likely to be suita-
ble for evaluating the risk of adverse events in pregnant
mothers who are inadvertently exposed to antimalarial
treatments in the first trimester. However, the events must
first be detected before case control studies can be con-
ducted. Establishing and maintaining detailed antenatal
and pregnancy registers to collect good quality data on
exposure to medicines during all the trimesters of preg-
nancy will facilitate detection of potential adverse effects.
Several African countries currently maintain antenatal reg-
isters as part of their routine health service data collection
systems and such registers should be revised to capture
data on drug safety. In addition, the collection of data on
antimalarial drug exposure during pregnancy should be a
mandatory requirement for the national health manage-
ment information systems. At delivery, at the time of rou-
tine vaccination or at any point of contact with the health
care system during the first year after delivery, a follow-up
assessment of serious adverse events could then be con-
ducted.
Active population-based evaluation of marketed products 
post-authorization
Prospective studies of a reasonably sized cohort exposed
to treatments and assessed for any subsequent AEs could
be used to monitor relatively common events. Active sur-
veillance requires prospective follow-up of a given popu-
lation to determine the incidence of adverse events in
those exposed to a given medicine. This approach is prob-
ably the most ideal, yet least pragmatic of all the phar-
maco-epidemiological methods because it is very
expensive and laborious. A major challenge for prospec-
tive cohort studies will be the identification of treated
(exposed) patients. However, in areas where there are
well-established prospective demographic surveillance
sites (DSS) in Africa (see the IN-DEPTH network), a PV
system could be linked to the DSS sites. A sample of the
population under surveillance (ideally children less than
five years old and pregnant women) would be selected
and followed for an extended period (1–3 years). Moni-
toring for adverse events would begin at the time of first
antimalarial treatment, with periodic follow-up of partic-
ipants for 1–2 months following each antimalarial treat-
ment. Where DSS systems are lacking, communities living
within the catchment areas for the sentinel sites used for
monitoring antimalarial treatment within the framework
of the East African Network for Monitoring Antimalaria
Treatment (EANMAT), the West African Network for
Monitoring Antimalaria Treatment (WANMAT I and II)
and the Horn of Africa Network for Monitoring Antima-
laria Treatment (HANMAT) could be used to establish a
targeted active population-based surveillance. In addi-
tion, in countries with a policy of home-based manage-
ment of fevers such as Uganda, active surveillance for drug
safety could be conducted by drug distributors. Such
approaches would require substantial financial and
human resource investment. However, costs could be
reduced if they were embedded within the broader frame-
work for monitoring and evaluation of the impact of
malaria interventions, a key requirement to track the
achievement of the millennium development goals
(MDGs) [18,19].
Is pharmacovigilance of antimalarial treatment in Africa 
possible?
PV for antimalarials and other drugs will be challenging in
Africa. Transparency in the management of drug safety
issues must be ensured. Optimal risk management cannot
be guaranteed unless access to information for patients,
health care providers and the community in general is
improved. The World Health Organisation regional and
sub-regional networks should facilitate member countries
to create a database on ADRs reported in the African
region for all newer antimalarial medicinal products. The
level of accessibility to this database by health care profes-
sionals and the public should be defined from the outset.
Country-specific proposals or strategic plans for PV
should be developed by national malaria control pro-
grammes and national drug regulatory bodies focusing on
needs assessment and the priority data required. In estab-
lishing sustainable pharmacovigilance systems for anti-
malarials in Africa, countries will need to critically assess
the system that will be used for detection, evaluation of
severity and evaluation of relationship of adverse events.
Practical issues of how such reporting will be done, and by
whom, will need to be addressed. After a system has been
designed, the capacity for conducting the work will need
to be strengthened or established. In order to build capac-Malaria Journal 2006, 5:50 http://www.malariajournal.com/content/5/1/50
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ity for PV, a conceptual model developed for strengthen-
ing multi-disease surveillance at country level within the
WHO region for Africa, has been adapted [20]. Based on
this model, the core and the support functions for phar-
macovigilance planning (PVP) and capacity strengthen-
ing, have been identified (Figure 2).
Conclusion
Pharmacovigilance has evolved over time in developed
countries. Although inadequate infrastructure and limited
resources (both financial and human) pose challenges to
implementing PV in developing countries, increased vul-
nerability of local populations makes drug safety moni-
toring imperative. Establishing systems for PV in Africa
will be the initial step. Assessment of strengths and weak-
nesses, expansion of existing infrastructure, and develop-
ment of programs to educate, motivate, and provide
feedback will be essential to help build capacity for PV.
Standardizing methods of reporting, including
approaches for defining events, determining severity, and
assessing causal relationships will also be important. Inte-
grating PV for malaria with other existing systems, such as
monitoring for adverse events following immunization,
and newer programs to monitor safety of treatment for
other diseases, including antiretroviral therapy in HIV/
AIDS, will likely be needed to leverage resources and
avoid duplication of efforts. Once PV systems are opera-
tional, rigorous and continuous quality assurance and
conduct of replicable validation studies will be critical if
PV is to be successful. Such assessments will also help to
determine the best practices with respect to the frequency
of safety data collection and analysis, and the optimal
combination of methods for PV. PV in Africa should be
possible, but realistic assessment of the challenges and
introduction of novel solutions will be needed to build
sustainable programs. The present momentum for PV
should be harnessed to develop innovative proposals for
PV in Africa [2]. Initially, monitoring activities could tar-
get antimalarial drugs, but ultimately PV should be
expanded to include safety monitoring of all drugs.
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Conceptual model for strengthening pharmacovigilance in Africa modified from the model for strengthening multi disease sur- veillance in the WHO/African region [20] Figure 2
Conceptual model for strengthening pharmacovigilance in Africa modified from the model for strengthening multi disease sur-
veillance in the WHO/African region [20].
Core PV Activities
• AE/ADR event and signal detection 
• AE/ADR verification 
• AE/ADR data reporting 
• AE/ADR data synthesis and analysis 
• Generation of hypotheses on new AE/ADR signals 
• Dissemination and feedback on AE/ADR 
• Supervision and monitoring of PV system 
Organizational Issues
• Vertical disease-specific approach vs. integration 
of all PV under one agency 
• Role of research institutions and universities 
• Administrative structure 
• Role of industry 
Monitoring Issues
• How to detect events? 
• How to grade severity? 
• How to classify relationship? 
• How to determine expectedness? 
• What events to report? 
• Pathway for reporting? 
Individual Issues
• Motivation/incentives schemes for reporting 
• Education/motivation for high quality reporting 
• Job satisfaction 
Improved PV
• Prompt and timeliness of ADR reports 
• ADR data utilization 
• Rapid feedback and follow up 
Support 
functions
• Training 
• Communication
• Resources 
• Logistics 